MannKind Corp. (MNKD)

[mc67]

And then there is the rest of the world...

All these figures we have just reviewed are for sales made only in the United States. Since the United States represents 29% of Sanofi's worldwide sales, a successful Afrezza, sold worldwide, could triple profits and earnings, making a price near $30 quite possible, should the stock remain at a conservative PE of 15 and a lot more if investors become more enthusiastic about MNKD's future.

Caution: these numbers work only if the drug is a hit with doctors and patients

http://seekingalpha.com/article/2849316-a-new-price-estimate-now-that-afrezza-is-launching